Is TB-500 Legal in 2026? FDA, WADA and State Rules Explained

Written by Dr. Andrii Kaleniuk. Updated November 10, 2026.

Is TB-500 legal? Not as an approved medicine: as of November 2026 there is no FDA-approved TB-500 product in the United States, and companies that sell it online as a "research chemical" are still exposed to the charge of selling an unapproved drug. What changed in late 2026 is narrower. A draft policy from the US Department of Health and Human Services (HHS), announced October 28 and published October 30, says federal regulators do not intend to take action against licensed pharmacies that compound one specific form of TB-500 for an individual patient with a valid prescription, under strict conditions. (Compounding means a pharmacy prepares a drug for one patient.) That policy is a draft, it is not binding, and public comments close on November 13, 2026. For competitive athletes nothing has changed: TB-500 is banned at all times under the World Anti-Doping Agency (WADA) list. And legal is not the same as safe: FDA's own scientists recommended against it for lack of human safety data. This explainer contains no dosing or sourcing information.

TB-500 is a short synthetic peptide based on a fragment of thymosin beta-4, a protein the body makes naturally. FDA lists it as "Thymosin beta-4 fragment (LKKTETQ), also known as TB-500," the letters being the amino-acid sequence. In its 2026 review, FDA looked at two forms: TB-500 free base and TB-500 acetate, a salt form. The difference matters because the new HHS policy names only the acetate form. For background, see what TB-500 is.

No. As of November 2026 there is no FDA-approved TB-500 drug. FDA evaluated TB-500 only as a "bulk drug substance", a raw ingredient that pharmacies might use for compounding, not as a finished medicine. Compounded drugs, even when allowed, are not FDA-approved: the HHS policy states this directly, saying "Compounded drugs are not FDA-approved." No company has submitted the clinical trial evidence approval requires. The wider 2026 rule changes for peptides are covered in our guide to FDA peptide rules in 2026.

When a substance is nominated for use in pharmacy compounding, FDA sorts it into categories while it is under review. In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)" in Category 2, the group of substances that "may present significant safety risks."

By April 2026 the picture had shifted. FDA's category page, current as of April 22, 2026, lists TB-500 under "Bulk drug substances nominated but withdrawn," because the people who nominated it withdrew their nominations. This was not a clean bill of health. The same FDA page says the agency "lacks important information regarding any safety issues," that TB-500 "may pose risk for immunogenicity for certain routes of administration" (meaning it could trigger an immune reaction), and that FDA "has not identified any human exposure data."

FDA then reviewed TB-500 on its own initiative for a meeting of its Pharmacy Compounding Advisory Committee (PCAC) on July 23 and 24, 2026. The evaluation, dated May 15, 2026, considered TB-500 for wound healing by injection under the skin or into muscle. Its findings were blunt:

FDA recommended not adding TB-500 to the 503A bulks list, the list of ingredients pharmacies may legally compound with. The advisory committee, whose votes are not binding, disagreed narrowly: it voted 8 to 6, with one abstention, in favour of TB-500 for wound healing, according to the American Med Spa Association.

On October 28, 2026, HHS announced a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," published in the Federal Register on October 30 (91 Fed. Reg. 68526, docket HHS-OASH-2026-0496). It covers six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. "Enforcement discretion" means the government says it will not prosecute certain activity, even though the activity has not been formally made lawful.

Under the draft, HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" that compounds these peptides, if all conditions are met. According to summaries by the law firms Arnold & Porter and Holland & Knight, those conditions include:

The policy is interim, pending a final 503A bulks rule, and may be revisited if safety problems appear. According to Arnold & Porter, FDA's drug centre (CDER) recommended against each of the six peptides, and a citizen petition from the Partnership for Safe Medicines (docket FDA-2026-P-13366) opposes the move. The same issues for BPC-157 are covered in is BPC-157 legal.

Headlines that say TB-500 is "now legal" go further than the text. As of November 2026, the policy:

Many websites sell TB-500 labelled "for research use only, not for human consumption." Under federal law, intended use is what counts, not the label. On August 24, 2026, FDA's drug centre sent warning letters to five peptide sellers charging them with selling unapproved new drugs. The letters said website evidence "establishes that your products are intended to be drugs for human use," pointing to features such as peptide dosing calculators and the sale of bacteriostatic water, which is used to mix injections.

Those letters named GLP-1 drugs and other peptides, not TB-500, and we found no FDA warning letter naming TB-500 specifically. But the reasoning applies to any peptide sold this way, and the label says nothing about purity, sterility or identity. We also found no source showing that TB-500 is listed as a federally controlled substance; its legal problems come from drug-approval law, not drug-scheduling law.

Yes. Thymosin beta-4, including TB-500, is prohibited at all times, in and out of competition, under the S2 section of the WADA Prohibited List, which covers peptide hormones, growth factors and related substances. Sport Integrity Australia notes concern that it may promote cancer-cell growth and that its safety is unknown. A prescription or pharmacy compounding does not change this: a tested athlete who tests positive faces a violation unless a therapeutic use exemption has been granted.

The penalties are real. In January 2016, the Court of Arbitration for Sport upheld a WADA appeal and banned 34 past and present Essendon AFL players for two years over thymosin beta-4. A testing company reports that Canada's anti-doping agency, the CCES, sanctioned an athlete for four years for BPC-157 and TB-500; we could not confirm the date. We did not find a confirmed horse-racing sanction specifically for TB-500, so we make no claim about one.

They can, but as of November 2026 we found no state law that names TB-500 specifically. State pharmacy boards still decide what pharmacies may do. Two examples:

Outside the US, rules differ. In Australia, TB-500 is a Schedule 4 prescription-only substance that is not approved by the Therapeutic Goods Administration (TGA), a research-use-only label is no defence, and the TGA issued an alert in April 2026.

Not necessarily. Legal status and safety are separate questions. The HHS policy is about enforcement priorities, not a finding that TB-500 works or is safe. FDA's review found no human studies, no evidence to judge effectiveness and a risk of immune reactions, and the empty adverse-event search is not reassurance, since products sold outside regulated channels are rarely reported. What is known and unknown about harms is covered in TB-500 side effects, and the claims about recovery are weighed in TB-500 for muscle recovery.

If you are an athlete weighing an injury treatment, ask:

If you are comparing recovery peptides, our BPC-157 vs TB-500 comparison sets out what the evidence does and does not show.

As of November 2026, TB-500 is not an FDA-approved drug. A draft HHS policy means federal regulators say they will not act against licensed 503A pharmacies that compound TB-500 acetate injections for prescribed patients under strict conditions, but the policy is not binding, is open for comment until November 13, 2026, excludes research-use-only material and leaves state law in place. For tested athletes, TB-500 remains banned at all times under WADA rules. Whatever its legal status, there is still no good human evidence that it is safe or that it works.

This article summarizes regulatory documents and news reports for general information as of November 10, 2026. It is not legal or medical advice and contains no dosing or sourcing information. Rules may change after the HHS comment period closes.